These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Oral ciprofloxacin in refractory gram-negative bacillary infections. Bryant RE; Hartstein AI Int J Clin Pharmacol Res; 1987; 7(3):187-94. PubMed ID: 3596862 [TBL] [Abstract][Full Text] [Related]
8. Ciprofloxacin in the treatment of gram-negative bacillary meningitis. Schönwald S; Beus I; Lisić M; Car V; Gmajnicki B Am J Med; 1989 Nov; 87(5A):248S-249S. PubMed ID: 2589372 [TBL] [Abstract][Full Text] [Related]
9. Antibacterial efficacy of ciprofloxacin in a case of endocarditis due to Cardiobacterium hominis. Vogt K; Klefisch F; Hahn H; Schmutzler H Zentralbl Bakteriol; 1994 Jun; 281(1):80-4. PubMed ID: 7803934 [TBL] [Abstract][Full Text] [Related]
10. Ciprofloxacin vs. cefotaxime regimens for the treatment of intra-abdominal infections. Hoogkamp-Korstanje JA Infection; 1995; 23(5):278-82. PubMed ID: 8557385 [TBL] [Abstract][Full Text] [Related]
11. Correlation of pharmacokinetic parameters to efficacy of antibiotics: relationships between serum concentrations, MIC values, and bacterial eradication in patients with gram-negative pneumonia. Schentag JJ Scand J Infect Dis Suppl; 1990; 74():218-34. PubMed ID: 2097710 [TBL] [Abstract][Full Text] [Related]
12. Treatment of respiratory tract infections with ciprofloxacin. Raoof S; Wollschlager C; Khan F J Antimicrob Chemother; 1986 Nov; 18 Suppl D():139-45. PubMed ID: 3804902 [TBL] [Abstract][Full Text] [Related]
13. Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin. Scully BE; Jules K; Chin NX; Neu HC Am J Med; 1987 Apr; 82(4A):336-8. PubMed ID: 3578324 [TBL] [Abstract][Full Text] [Related]
14. Ciprofloxacin in the treatment of acute and chronic osteomyelitis: a review. Norrby SR Scand J Infect Dis Suppl; 1989; 60():74-8. PubMed ID: 2667110 [TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic bacterial prostatitis with ciprofloxacin. Langemeyer TN; Ferwerda WH; Hoogkamp-Korstanje JA; de Leur EJ; van Oort H; Schipper JJ; van der Wal T Pharm Weekbl Sci; 1987 Dec; 9 Suppl():S78-81. PubMed ID: 3325933 [TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of ciprofloxacin against aerobic and anaerobic bacteria from clinical isolates. Klietmann W; Focht J; Nösner K Arzneimittelforschung; 1987 Jun; 37(6):661-6. PubMed ID: 2822054 [TBL] [Abstract][Full Text] [Related]
17. Intravenous ciprofloxacin dosing in a morbidly obese patient. Caldwell JB; Nilsen AK Ann Pharmacother; 1994 Jun; 28(6):806. PubMed ID: 7919576 [No Abstract] [Full Text] [Related]
18. Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding. Sifuentes-Osornio J; Macías A; Amieva RI; Ramos A; Ruiz-Palacios GM Am J Med; 1989 Nov; 87(5A):202S-205S. PubMed ID: 2686425 [TBL] [Abstract][Full Text] [Related]
19. E-4695, a new C-7 azetidinyl fluoronaphthyridine with enhanced activity against gram-positive and anaerobic pathogens. Guinea J; Gargallo-Viola D; Robert M; Tudela E; Xicota MA; Garcia J; Esteve M; Coll R; Pares M; Roser R Antimicrob Agents Chemother; 1995 Feb; 39(2):413-21. PubMed ID: 7726507 [TBL] [Abstract][Full Text] [Related]
20. The role of fluoroquinolones in the management of skin, soft tissue, and bone infections. Fong IW Clin Invest Med; 1989 Feb; 12(1):44-9. PubMed ID: 2646054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]